RFK Jr. and the Category 2 reversal: a clear timeline of what's actually happened
TL;DR
- In 2023 the FDA placed several research peptides on Category 2, blocking 503A compounding pharmacies from preparing them.
- In February 2026, HHS proposed returning these peptides to Category 1, pending a formal Federal Register notice.
- Nothing is final yet — the July 2026 PCAC meeting is the next public checkpoint.
What it is
This is a regulatory story about how research peptides (in plain English: lab-made short protein chains studied for healing, sleep, and metabolic effects) are categorized by the US Food and Drug Administration. The FDA sorts ingredients used by 503A compounding pharmacies (in plain English: small pharmacies that make custom prescriptions) into Category 1 (allowed) and Category 2 (not allowed pending review). Several familiar names — including BPC-157, TB-500, thymosin alpha-1, and Selank — landed in Category 2 in 2023, which is why patients suddenly lost access.
How it works
Think of the FDA Categories like a kitchen pantry with two shelves. Category 1 ingredients sit on the open shelf — pharmacists can reach for them. Category 2 ingredients are behind a locked cabinet while safety and quality questions are reviewed. The Pharmacy Compounding Advisory Committee (PCAC) is the group that helps the FDA decide which shelf each ingredient belongs on. A change in administration, new safety data, or a public petition can prompt a fresh review.
Who asks about it
Patients who were on a peptide protocol in 2022 and lost access in 2023 want to know one thing: when can my pharmacy refill this? Clinicians want to know what they can legally prescribe. Both groups follow the headlines because access has shifted twice in three years.
What the research says
The 2023 Category 2 placements were tied to gaps in US-based safety data and concerns about identity and purity. Peptide research itself is decades old, but much of the clinical literature on items like BPC-157 and Selank comes from Russian and animal studies. Since 2024, several US researchers and patient advocacy groups have pushed for a structured review rather than a blanket block. The February 2026 HHS announcement is the first signal that federal posture is shifting. Final status is associated with the FDA Federal Register notice, not the announcement alone.
What to know before considering it
Nothing has changed at the pharmacy counter yet. As of May 2026, 503A pharmacies still cannot legally compound the Category 2 peptides. Marketplaces or websites selling them as "research only" are operating outside the licensed clinical pathway. The safest move is to wait for the Federal Register notice and work with a licensed clinician.
The Halftime POV
Regulation moves slowly, and headlines move fast. We track the actual Federal Register entries and PCAC dockets so patients do not have to. When the reversal is real, we will say so on the same day — and not before.
Related reading:
- Category 1 vs Category 2: what the FDA labels mean
- RFK Jr. and peptide reclassification: the bigger picture
- What to watch at the July 2026 PCAC meeting
FAQ
Q: Did RFK Jr. change peptide law? A: No single person changes FDA law. HHS leadership can direct review, but final classification runs through the FDA's Federal Register process.
Q: Is BPC-157 legal right now? A: As of May 2026, BPC-157 remains on Category 2 pending the proposed reversal. Watch the Federal Register for final notice.
Q: Where can I follow the official process? A: The FDA Federal Register page and the PCAC docket are the two primary public sources.
Disclaimer
As of May 2026, several peptides discussed in this article — including BPC-157, TB-500, thymosin alpha-1, and Selank — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. Join the waitlist for updates.
Sources
- US Food and Drug Administration. Federal Register notices, 2023-2026. https://www.federalregister.gov/agencies/food-and-drug-administration
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting materials. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee-pcac
- US Department of Health and Human Services. Press releases, February 2026.
- FDA Drug Quality and Security Act overview. https://www.fda.gov/drugs/human-drug-compounding
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Are peptides legal in the US right now?
Several research peptides are currently classified by the FDA as Category 2, which means 503A compounding pharmacies cannot use them. The status is under review.
What did RFK Jr. say about peptides?
During and after his 2025 HHS confirmation hearings, he publicly supported revisiting peptide access. In February 2026, HHS announced a proposed path back to Category 1.
When could the reversal be official?
Final timing depends on the FDA Federal Register notice and the July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.